IMAB I-MAB ADS (N Shares)

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025.

Details are as follows:

24th Annual Needham Virtual Healthcare Conference 
Conference Date:April 7-10, 2025
Format:Company Presentation and one-on-one meetings
Presentation Time:Monday, April 7, 2025, 8:45 to 9:25 AM ET
Webcast Link:Register
  

About I-Mab

I-Mab (NASDAQ: IMAB) is a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit us at: and follow us on and .

I-Mab Investor & Media Contacts

PJ Kelleher

LifeSci Advisors







EN
26/03/2025

Underlying

IMABI-MAB ADS (N Shares)

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on I-MAB ADS (N Shares)

 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Present at Jefferies Global Healthcare Conference

I-Mab to Present at Jefferies Global Healthcare Conference ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig. I-Mab also recently announced that new data on givastomig has been accepted for a...

May 20, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Reports First Quarter 2025 Financial Results and Provides Busine...

I-Mab Reports First Quarter 2025 Financial Results and Provides Business Update Prioritization of givastomig as I-Mab’s lead program positions the Company for clinical progressNew givastomig combination data selected for mini-oral presentation at ESMO GI, being held July 2-5 in Barcelona, SpainStrong financial position supported by $168.6 million of cash and cash equivalents, and short-term investments as of March 31, 2025; provides runway into 2027, through expected clinical readouts for givastomig ROCKVILLE, Md., May 15, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (th...

May 15, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ...

I-Mab Announces Givastomig Abstract Accepted for Oral Presentation at ESMO GI 2025 The ESMO Gastrointestinal Cancers Congress to be held July 2-5 in Barcelona ROCKVILLE, Md., April 30, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that an abstract for a combination study of givastomig plus nivolumab and chemotherapy has been accepted for a mini-oral presentation at the ESMO Gastrointestinal Cancers Congress 2025, which will be...

April 30, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab Reports Full Year 2024 Financial Results and Provides Business U...

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update Continued positive momentum in givastomig Phase 1b combination trial in first-line gastric cancer, with topline dose escalation data (n=17) expected in 2H 2025Enrollment completed ahead of schedule in the first givastomig Phase 1b dose expansion cohort; momentum continues in the second expansion cohortStrong financial position supported by $173.4 million of cash and cash equivalents, and short-term investments as of December 31, 2024; provides runway into 2027, through expected clinical readouts for givastomig ROCK...

April 3, 2025 1 EN
 PRESS RELEASE
Free
IMAB I-MAB ADS (N Sh...

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB), a US-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in 24th Annual Needham Virtual Healthcare Conference, being held April 7-10, 2025. Details are as follows: 24th Annual Needham Virtual Healthcare Conference Conference Date:April 7-10, 2025Format:Company Presentation and one-on-one meetingsPresentation Ti...

March 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch